- First primary endpoint achieved: ozarelix provided testosterone suppression to castration level at 130 mg every four weeks QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today presented detailed positive Phase 2 results in hormone-dependent, inoperable prostate cancer for its luteinizing hormone-releasing hormone (LHRH) antagonist compound, ozarelix. Results were presented at the Societe Internationale d'Urologie (SIU) Meeting in Cape Town, South Africa by Professor Frans M.J. Debruyne from the Department of Urology, University Medical Center in Nijmegen, The Netherlands, and Chairman of the European Urology Association. Data showed that the first primary efficacy endpoint of the study of finding a tolerable dosage regimen ensuring continuous suppression of testosterone at castration level (